Oncolytics Biotech® Wins FDA Fast Track Designation for Pelareorep in Later-Stage Anal Cancer
Oncolytics Biotech Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep. The designation covers pelareorep in combination with a checkpoint inhibitor to treat patients with inoperable, locally recurrent, or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or could not tolerate, one or more prior lines of systemic therapy.
What Fast Track Designation Means
The FDA created Fast Track designation specifically to speed up the development and review of therapies that target serious diseases and fill significant unmet medical needs. As a result, the designation opens several doors for Oncolytics: it allows the company to interact with the FDA more frequently throughout development, it permits a rolling review of a future Biologics License Application, and it establishes eligibility for Priority Review, if applicable.
Building on Positive FDA Feedback
Oncolytics views this designation as further validation of pelareorep’s potential to address a major gap in advanced SCAC care. Notably, the announcement follows the encouraging feedback the company received during its April 2026 meeting with the FDA about a potential registrational development strategy. Because of that feedback, Oncolytics now believes it has a clear regulatory framework to advance pelareorep toward a pivotal study.
“This Fast Track designation represents another important regulatory milestone for Oncolytics and reflects the significant progress we have made over the past twelve months in advancing pelareorep toward potential registration,” said Jared Kelly, Chief Executive Officer of Oncolytics. “During that time, we have received Fast Track designation in both metastatic colorectal cancer and squamous cell anal carcinoma, achieved important FDA alignment on registrational development strategies, strengthened our intellectual property portfolio, and continued to generate compelling clinical data across our gastrointestinal oncology programs. Our April meeting with the FDA provided important clarity regarding a potential registrational pathway for pelareorep in second-line and later anal cancer, reinforcing our confidence in the program and our strategy to address an area of significant unmet need. We believe these milestones continue to de-risk our development programs while positioning the Company to deliver meaningful value for patients and shareholders.”
Strong Clinical Results Drive the Decision
Encouraging efficacy data from the company’s GOBLET study directly supports the new designation. In that study, pelareorep combined with a checkpoint inhibitor treated patients with advanced SCAC whose disease had progressed after prior therapy. The results stood out sharply against historical benchmarks: the combination produced an objective response rate of roughly 30%, which more than doubled the response rates previously reported in this setting. Furthermore, patients experienced a median duration of response of about 15.5 months, compared with 9.5 months historically, and the 12-month overall survival rate reached 82%, far exceeding the historical figure of 45.7%.
Addressing a Nearly $1 Billion Unmet Need
Today, checkpoint inhibitor plus chemotherapy serves as the first-line standard of care in SCAC. However, once a patient’s disease progresses after that treatment, no FDA-approved therapy exists—a gap that represents a significant unmet medical need and a U.S. commercial opportunity approaching $1 billion annually. While checkpoint therapy is approved as a single agent following progression or intolerance to platinum-based chemotherapy alone, regulators have yet to approve any checkpoint inhibitor for patients who progress after the current first-line standard of care.
The Third GI Cancer Milestone
This SCAC designation marks the third gastrointestinal cancer Fast Track designation the FDA has granted to pelareorep. It follows earlier designations in KRAS-mutated metastatic colorectal cancer in February 2026 and in pancreatic cancer in late 2022. Taken together, these three designations reinforce pelareorep’s potential to address serious unmet needs and validate the company’s strategy of pursuing registration across high-value gastrointestinal cancer indications.
About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy that works through a dual mechanism of action. It selectively replicates in tumor cells while simultaneously activating both innate and adaptive anti-tumor immune responses. In doing so, it upregulates key inflammatory cytokines, which in turn drives the formation of tertiary lymphoid structures and expands tumor-infiltrating lymphocytes. Across multiple solid tumor types, clinical studies have shown that pelareorep can enhance the activity of checkpoint inhibitors and other anti-cancer therapies.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational, intravenously delivered, double-stranded RNA immunotherapeutic agent. To date, pelareorep has delivered encouraging results in multiple first-line pancreatic cancer studies, in two randomized Phase 2 studies in metastatic breast cancer, and in early-phase studies in anal and colorectal cancer. The therapy works by converting immunologically “cold” tumors into “hot” ones, activating both innate and adaptive immune responses to spark anti-cancer activity.
Currently, the company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors across metastatic gastrointestinal cancers, where the therapy has now earned Fast Track designation for colorectal, anal, and pancreatic cancer. In addition, Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. To learn more, visit www.oncolyticsbiotech.com, review the company’s latest investor news, or follow Oncolytics on LinkedIn and on X @oncolytics.
